Ally Bridge Group (NY) LLC 4
4 · ProMIS Neurosciences Inc. · Filed Feb 5, 2026
Research Summary
AI-generated summary of this filing
ProMIS (PMN) 10% Owner ABG Management Ltd. Buys 700,741 Shares
What Happened
ABG Management Ltd., reported as a 10% owner of ProMIS Neurosciences (PMN), purchased 700,741 common shares in an open-market/private purchase on February 3, 2026 at $12.13 per share for a total of $8,499,988. The filing also reports acquisition of warrants tied to the same transaction (700,741 warrants in aggregate) that were purchased together with the common shares.
Key Details
- Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (timely).
- Common shares purchased: 700,741 at $12.13 each = $8,499,988.
- Derivative/warrants: Warrants to purchase 700,741 common shares were acquired alongside the shares (price for warrants not separately stated; purchased as part of the $12.13 per-share aggregate).
- Warrant terms: exercisable immediately; expire on the earlier of (i) within 60 days after a defined "Milestone Event" (public release/8-K of topline PMN310 single ascending dose data) or (ii) February 3, 2031.
- Holdings disclosed by related entities: the filing lists common shares held of record across affiliated entities totaling 943,090 shares (407,230 + 329,760 + 206,100) and warrants to purchase 700,741 shares.
- Beneficial ownership: Footnotes tie these holdings to affiliated funds and to Mr. Fan Yu (controlling stockholder of ABG Management Ltd. and related entities), who may be deemed to share beneficial ownership. Several affiliated entities will file Form 3s and subsequent Forms 4 jointly.
- Filing timeliness: Reported within two business days (no late filing flag).
Context
This is an institutional purchase by a 10% owner and affiliated funds, not an individual corporate officer executing a routine sale or tax-related disposition. The package includes immediately exercisable warrants tied to a clinical-data milestone for PMN310, which could affect timing of any warrant exercises but does not, by itself, indicate management sentiment. As always, purchases can be interpreted as a positive signal but do not guarantee future performance.
Insider Transaction Report
- Purchase
Common Shares
[F1][F2][F3][F4][F5]2026-02-03$12.13/sh+700,741$8,499,988→ 943,090 total(indirect: See Footnote) - Purchase
Warrants
[F1][F6][F3][F4][F5][F7]2026-02-03+700,741→ 700,741 total(indirect: See Footnote)Exercise: $14.40→ Common Shares (700,741 underlying)
Footnotes (7)
- [F1]The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share.
- [F2]The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited.
- [F3]Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.
- [F4]Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.
- [F5]Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.
- [F6]The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310.
- [F7]The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited.